Moderna Shares Surge 42% as Company Expands Beyond COVID Vaccines
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Stock Surge: Moderna shares surged nearly 15% on Friday to around $69, marking a 42% increase over the past month, significantly outperforming the S&P 500's 7.49% return, reflecting strong market confidence in its future prospects.
- Diversification Strategy: During its Science Day event, Moderna highlighted progress in cancer treatments, autoimmune diseases, and next-generation mRNA medicines, indicating its commitment to becoming a diversified drug developer beyond COVID vaccines.
- Cancer Prevention Program: The company's first cancer prevention program, mRNA-4194, aimed at patients with Lynch syndrome, has garnered investor attention, showcasing its innovative potential in the oncology field.
- Flu Vaccine Progress: An FDA advisory panel voted 9-0 in favor of the flu vaccine mRNA-1010 for adults aged 50 and older, with a final decision expected on August 5, 2026, further boosting market confidence in Moderna's future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 59.750
Low
17.00
Averages
32.47
High
63.00
Current: 59.750
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Influenza Vaccine Gains FDA Support
- Vaccine Development Progress: Moderna's influenza vaccine, mRNA-1010, has been submitted for FDA approval earlier this year, with a decision expected by August 5; if approved, it could position the company as a leader in the flu market, despite existing vaccines typically showing efficacy between 40% and 60%.
- Clinical Trial Performance: In phase 3 studies targeting high-risk individuals aged 50 and older, mRNA-1010 outperformed existing approved vaccines, demonstrating its potential to reduce severe cases, hospitalizations, and deaths, thereby enhancing its competitive edge in the market.
- Positive Market Reaction: Following the unanimous vote of support from the FDA advisory committee for mRNA-1010, Moderna's stock surged, indicating that the market has largely priced in a favorable outcome, although significant price movement may not occur post-approval.
- Future Growth Potential: While the flu vaccine market is relatively small, valued at approximately $8.9 billion last year, Moderna's extensive pipeline, including a personalized cancer vaccine and an HIV vaccine, could drive strong revenue and earnings growth over the next five years.
See More
Moderna Shares Surge 42% as Company Expands Beyond COVID Vaccines
- Stock Surge: Moderna shares surged nearly 15% on Friday to around $69, marking a 42% increase over the past month, significantly outperforming the S&P 500's 7.49% return, reflecting strong market confidence in its future prospects.
- Diversification Strategy: During its Science Day event, Moderna highlighted progress in cancer treatments, autoimmune diseases, and next-generation mRNA medicines, indicating its commitment to becoming a diversified drug developer beyond COVID vaccines.
- Cancer Prevention Program: The company's first cancer prevention program, mRNA-4194, aimed at patients with Lynch syndrome, has garnered investor attention, showcasing its innovative potential in the oncology field.
- Flu Vaccine Progress: An FDA advisory panel voted 9-0 in favor of the flu vaccine mRNA-1010 for adults aged 50 and older, with a final decision expected on August 5, 2026, further boosting market confidence in Moderna's future.
See More
Software Stocks Rally as Moderna Surges 11% on Long-Term Strategy
- Software Sector Strength: Despite a broader tech sector decline, the iShares Expanded Tech-Software Sector ETF (IGV) rose by 3%, with Microsoft and Salesforce both gaining over 4%, indicating strong market confidence in software companies that may drive future investment inflows.
- Moderna's Strategic Shift: Moderna's stock surged 11% after detailing its long-term strategy at its annual Science Day, expanding beyond vaccines to include mRNA-based oncology and rare disease treatments, showcasing its potential for growth in the biotech sector.
- Healthcare Sector Rally: The S&P 500 healthcare sector outperformed, rising over 2%, with Veeva Systems and Eli Lilly both up 7%, reflecting increased investor confidence in the healthcare industry and signaling potential growth opportunities ahead.
- ON Semiconductor's Acquisition: ON Semiconductor announced a nearly $7 billion all-stock deal to acquire Synaptics, resulting in a 23% stock drop, yet it is expected to increase the company's total addressable market by $30 billion, highlighting its strategic expansion intentions in the semiconductor industry.
See More
Moderna's Flu Vaccine Progress Drives Stock Surge
- Vaccine Approval Imminent: Moderna's flu vaccine mRNA-1010 is expected to receive FDA approval within two months, a development that could position the company as a leader in the flu market, enhancing its competitive edge in biotechnology.
- Positive Market Reaction: Following the FDA advisory committee's unanimous vote in favor of mRNA-1010, Moderna's stock has surged approximately 100%, indicating that the market has likely priced in the positive expectations surrounding the vaccine.
- Rich Pipeline Potential: In addition to the flu vaccine, Moderna is developing the personalized cancer vaccine mRNA-4157 and an HIV vaccine, showcasing its R&D capabilities across multiple high-growth areas, with the potential for a broader product portfolio and revenue growth over the next five years.
- Market Size and Challenges: Although the flu vaccine market was estimated at $8.9 billion last year, Moderna's market cap stands at $24.5 billion, and with meager revenue from current products, the company must rely on the success of new products to support long-term growth.
See More
U.S. Supports Clinical Trials for Ebola Antibody Drug in Congo
- Clinical Trial Launch: The U.S. has provided doses of the experimental antibody drug MBP134 from Mapp Biopharmaceutical to combat the Ebola outbreak in Congo, marking the first direct support for clinical trials, although the exact number of doses remains undisclosed, potentially aiding future regulatory reviews.
- Epidemic Context: The Bundibugyo strain of Ebola has caused over 1,000 cases and 250 deaths in Congo, with the WHO declaring it a public health emergency, emphasizing the need for clinical trials to ensure safety before widespread use of treatments.
- Trial Collaboration: The clinical trial for the Mapp drug is sponsored by the WHO and conducted in partnership with the University of Oxford and the governments of Congo and Uganda, expected to commence in the coming weeks to assess the drug's efficacy and safety.
- Vaccine Development Progress: While vaccine trials are still in the pipeline, the WHO indicated that Phase 1 trials could begin in the UK and Uganda, involving candidates such as those developed by Oxford and the Serum Institute of India, reflecting ongoing global efforts to combat Ebola.
See More
Moderna's Vaccine Prospects Look Promising
- Stock Recovery: Moderna's stock has surged over 100% since the beginning of the year, reflecting a renewed investor confidence in the company's future potential, particularly against the backdrop of declining vaccine demand, indicating strong market belief in its mRNA technology.
- Product Launch Plans: The company aims to release three new vaccines between 2027 and 2028, including a combination flu and coronavirus vaccine, which will not only diversify its product line but also potentially create new revenue streams, enhancing its competitive position in the market.
- FDA Review Progress: The U.S. FDA advisory panel unanimously supported Moderna's flu vaccine candidate mRNA-1010, with a decision expected by August 5, which could pave the way for a market launch in the 2026-2027 flu season, marking a significant milestone for the company.
- Optimistic Market Outlook: Despite some risks, Moderna is accelerating its transition to a multi-product commercial stage, with investors eagerly anticipating future revenue drivers, especially following potential vaccine approvals, which may present opportunities for stock price increases.
See More
Moderna's Influenza Vaccine Gains FDA Support
- Vaccine Development Progress: Moderna's influenza vaccine, mRNA-1010, has been submitted for FDA approval earlier this year, with a decision expected by August 5; if approved, it could position the company as a leader in the flu market, despite existing vaccines typically showing efficacy between 40% and 60%.
- Clinical Trial Performance: In phase 3 studies targeting high-risk individuals aged 50 and older, mRNA-1010 outperformed existing approved vaccines, demonstrating its potential to reduce severe cases, hospitalizations, and deaths, thereby enhancing its competitive edge in the market.
- Positive Market Reaction: Following the unanimous vote of support from the FDA advisory committee for mRNA-1010, Moderna's stock surged, indicating that the market has largely priced in a favorable outcome, although significant price movement may not occur post-approval.
- Future Growth Potential: While the flu vaccine market is relatively small, valued at approximately $8.9 billion last year, Moderna's extensive pipeline, including a personalized cancer vaccine and an HIV vaccine, could drive strong revenue and earnings growth over the next five years.
See More
Moderna Shares Surge 42% as Company Expands Beyond COVID Vaccines
- Stock Surge: Moderna shares surged nearly 15% on Friday to around $69, marking a 42% increase over the past month, significantly outperforming the S&P 500's 7.49% return, reflecting strong market confidence in its future prospects.
- Diversification Strategy: During its Science Day event, Moderna highlighted progress in cancer treatments, autoimmune diseases, and next-generation mRNA medicines, indicating its commitment to becoming a diversified drug developer beyond COVID vaccines.
- Cancer Prevention Program: The company's first cancer prevention program, mRNA-4194, aimed at patients with Lynch syndrome, has garnered investor attention, showcasing its innovative potential in the oncology field.
- Flu Vaccine Progress: An FDA advisory panel voted 9-0 in favor of the flu vaccine mRNA-1010 for adults aged 50 and older, with a final decision expected on August 5, 2026, further boosting market confidence in Moderna's future.
See More
Software Stocks Rally as Moderna Surges 11% on Long-Term Strategy
- Software Sector Strength: Despite a broader tech sector decline, the iShares Expanded Tech-Software Sector ETF (IGV) rose by 3%, with Microsoft and Salesforce both gaining over 4%, indicating strong market confidence in software companies that may drive future investment inflows.
- Moderna's Strategic Shift: Moderna's stock surged 11% after detailing its long-term strategy at its annual Science Day, expanding beyond vaccines to include mRNA-based oncology and rare disease treatments, showcasing its potential for growth in the biotech sector.
- Healthcare Sector Rally: The S&P 500 healthcare sector outperformed, rising over 2%, with Veeva Systems and Eli Lilly both up 7%, reflecting increased investor confidence in the healthcare industry and signaling potential growth opportunities ahead.
- ON Semiconductor's Acquisition: ON Semiconductor announced a nearly $7 billion all-stock deal to acquire Synaptics, resulting in a 23% stock drop, yet it is expected to increase the company's total addressable market by $30 billion, highlighting its strategic expansion intentions in the semiconductor industry.
See More
Moderna's Flu Vaccine Progress Drives Stock Surge
- Vaccine Approval Imminent: Moderna's flu vaccine mRNA-1010 is expected to receive FDA approval within two months, a development that could position the company as a leader in the flu market, enhancing its competitive edge in biotechnology.
- Positive Market Reaction: Following the FDA advisory committee's unanimous vote in favor of mRNA-1010, Moderna's stock has surged approximately 100%, indicating that the market has likely priced in the positive expectations surrounding the vaccine.
- Rich Pipeline Potential: In addition to the flu vaccine, Moderna is developing the personalized cancer vaccine mRNA-4157 and an HIV vaccine, showcasing its R&D capabilities across multiple high-growth areas, with the potential for a broader product portfolio and revenue growth over the next five years.
- Market Size and Challenges: Although the flu vaccine market was estimated at $8.9 billion last year, Moderna's market cap stands at $24.5 billion, and with meager revenue from current products, the company must rely on the success of new products to support long-term growth.
See More
U.S. Supports Clinical Trials for Ebola Antibody Drug in Congo
- Clinical Trial Launch: The U.S. has provided doses of the experimental antibody drug MBP134 from Mapp Biopharmaceutical to combat the Ebola outbreak in Congo, marking the first direct support for clinical trials, although the exact number of doses remains undisclosed, potentially aiding future regulatory reviews.
- Epidemic Context: The Bundibugyo strain of Ebola has caused over 1,000 cases and 250 deaths in Congo, with the WHO declaring it a public health emergency, emphasizing the need for clinical trials to ensure safety before widespread use of treatments.
- Trial Collaboration: The clinical trial for the Mapp drug is sponsored by the WHO and conducted in partnership with the University of Oxford and the governments of Congo and Uganda, expected to commence in the coming weeks to assess the drug's efficacy and safety.
- Vaccine Development Progress: While vaccine trials are still in the pipeline, the WHO indicated that Phase 1 trials could begin in the UK and Uganda, involving candidates such as those developed by Oxford and the Serum Institute of India, reflecting ongoing global efforts to combat Ebola.
See More
Moderna's Vaccine Prospects Look Promising
- Stock Recovery: Moderna's stock has surged over 100% since the beginning of the year, reflecting a renewed investor confidence in the company's future potential, particularly against the backdrop of declining vaccine demand, indicating strong market belief in its mRNA technology.
- Product Launch Plans: The company aims to release three new vaccines between 2027 and 2028, including a combination flu and coronavirus vaccine, which will not only diversify its product line but also potentially create new revenue streams, enhancing its competitive position in the market.
- FDA Review Progress: The U.S. FDA advisory panel unanimously supported Moderna's flu vaccine candidate mRNA-1010, with a decision expected by August 5, which could pave the way for a market launch in the 2026-2027 flu season, marking a significant milestone for the company.
- Optimistic Market Outlook: Despite some risks, Moderna is accelerating its transition to a multi-product commercial stage, with investors eagerly anticipating future revenue drivers, especially following potential vaccine approvals, which may present opportunities for stock price increases.
See More
